Table 3.
Comparison of resistance to tetracycline, erythromycin, and clindamycin of GBS isolates with different serotypes, CC17 and hvgA
| Total (n = 93) | Serotypes (n,%) | CCs (n,%) | hvgA (n,%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Ia (n = 4) | Ib (n = 12) | III (n = 74) | IV (n = 3) | CC17 (n = 60) | Non-CC17 (n = 33) |
hvgA(+) (n = 62) |
hvgA(−) (n = 31) |
||
| Tetracycline | 87 (93.5%) | 4 (100%) | 11 (91.7%) | 69 (93.2%) | 3 (100%) | 57 (95.0%) | 30 (90.9%) | 60 (96.8%) | 27 (87.1%) |
| Erythromycin | 56 (60.2%) | 2 (50%) | 7 (58.3%) | 45 (60.8%) | 2 (66.7%) | 38 (63.3%) | 18 (54.5%) | 39 (62.9%) | 17 (54.8%) |
| Clindamycin | 61 (65.6%) | 1 (25%) | 8 (66.7%) | 50 (67.6%) | 2 (66.7%) | 40 (66.7%) | 21 (63.6%) | 46 (74.2%)a | 15 (48.4%) |
aCompared to the hvgA(+) isolates, P < 0.05